MétaCan
Menu
← Back to cohort

An Update on STEADY-PD III: A Phase 3 Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson’s Disease (P2.341)

2016· article· en· W2521940310 on OpenAlexaboutno aff
Tanya Simuni, Jillian Lowell, David Oakes, Karen Hodgeman, Rebecaa Harkin, Brittany M. Greco, Kevin Biglan

Bibliographic record

VenueNeurology · 2016
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsIsradipineParkinson's diseaseDiseaseMedicineInternal medicineReceptor

Abstract

fetched live from OpenAlex

Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist, is neuroprotective in in vitro/in vivo models of parkinsonism. Epidemiological data suggests a reduced risk of PD with chronic use of dihydropyridines. Our Phase II study found isradipine 10 mg daily to be safe and well tolerated in early Parkinson's disease (PD); a dosage that achieves serum concentrations found to be neuroprotective in animal models of PD. Methods: The study is a 36 month, Phase 3, parallel group, placebo-controlled study of the efficacy of isradipine 10mg daily in 336 participants with early PD as measured by the change in the Unified Parkinson Disease Rating Scale (UPDRS) Part I-III score. Secondary outcome measures include clinically meaningful measures of disability progression in early PD: 1) Time to initiation and utilization of dopaminergic therapy; 2) Time to onset of motor complications; 3) Change in non-motor disability. Exploratory measures include global measures of functional disability, quality of life, change in the ambulatory capacity, cognitive function and pharmacokinetic analysis. Results: The study was funded by NINDS and is being conducted at 55 Parkinson Study Group sites in US and Canada. As of October 23, 2015 335 subjects have been enrolled and there have been two premature withdrawals. The currently enrolled cohort is 69.3[percnt] male and 90.6[percnt] caucasian. Of the first 332 subjects, the mean (SD) age is 61.7 (9.6) years; total UPDRS is 26.9 (9.4); and MOCA is 28 (1.5). We anticipate enrollment to be completed by November 2015. Conclusion: This study represents a unique opportunity to evaluate the potential impact of a novel therapy to slow progression of PD disability and provide clinically meaningful benefits. Study supported by the NINDS U01NS080818 and U01NS080840

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0020.001
Open science0.0030.001
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0040.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.279
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→